A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders

Annals of the New York Academy of Sciences

Volumn 1327, Issue 1, 2014, Pages 112-130

  Gastfriend, David R ^a  

^a TREATMENT RESEARCH INSTITUTE   (United States)

Author keywords

Agonist; Antagonist; Comparative effectiveness research; Cost effectiveness; Medication; Pharmaceutical industry; Substance abuse

Indexed keywords

ACAMPROSATE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DISULFIRAM; METHADONE; NALTREXONE; DRUGS USED IN THE TREATMENT OF ADDICTION; NARCOTIC ANTAGONIST;

ABSTINENCE; ALCOHOL USE DISORDER; ALCOHOLISM; ARTICLE; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG ABUSE; DRUG INDUSTRY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; OPIATE ADDICTION; OPIOID USE DISORDER; OUTCOME ASSESSMENT; PSYCHOSOCIAL CARE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; MANPOWER; MULTIMODALITY CANCER THERAPY; NATIONAL HEALTH ORGANIZATION; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PROFESSIONAL STANDARD; PSYCHOTHERAPY; UNITED STATES;

ALCOHOL DETERRENTS; ALCOHOLISM; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG INDUSTRY; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; INDIVIDUALIZED MEDICINE; NARCOTIC ANTAGONISTS; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (U.S.); NATIONAL INSTITUTE ON DRUG ABUSE (U.S.); OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL ROLE; PSYCHOTHERAPY; UNITED STATES;

EID: 84915822708     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12538     Document Type: Article

References (95)

1. Murray, C.J. & A.D. Lopez. 2013. Measuring the global burden of disease. N. Engl. J. Med. 369: 448-457.
2. Bouchery, E.E., H.J. Harwood, J.J. Sacks, et al. 2011. Economic costs of excessive alcohol consumption in the U.S., 2006. Am. J. Prev. Med. 41: 516-524.
3. National Drug Intelligence Center (NDIC). 2011. The Economic Impact of Illicit Drug Use on American Society. Washington, DC: United States Department of Justice.
4. Office of the National Drug Control Policy (ONDCP). 2013. National drug control strategy. http://www.whitehouse.gov//sites/default/files/ondcp/policy-and-research3/ndcs_2013.pdf. Accessed on August 14, 2013.
5. Substance Abuse and Mental Health Services Administration. 2012. Results from the 2012 National Survey on Drug Use and Health: summary of national findings. Report No.: NSDUH Series H-44, HHS Publication No. (SMA) 12-4713. Rockville, MD: Substance Abuse and Mental Health Services Administration.
6. Berg, K.M., H.V. Kunins, J.L. Jackson, et al. 2008. Association between alcohol consumption and both osteoporotic fracture and bone density. Am. J. Med. 121: 406-418.
7. Howard, A.A., J.H. Arnsten & M.N. Gourevich. 2004. Effect of alcohol consumption and drug abuse on diabetes mellitus: a systematic review. Ann. Intern. Med. 140: 211-219.
8. Mertens, J., Y. Lu, S. Parthasarathy, et al. 2003. Medical and psychiatric conditions of alcohol and drug treatment patients in an HMO: comparison with matched controls. Arch. Intern. Med. 163: 2511-2517.
9. Sullivan, L.E., D.A. Fiellin & P.G. O'Connor. 2005. The prevalence and impact of alcohol problems in major depression: a systematic review. Am. J. Med. 118: 330-341.
10. Lindsey, M., W. Patterson, K. Ray & P. Roohan. 2007. Statistical Brief #3: Potentially Preventable Hospital Readmissions among Medicaid Recipients with Mental Health and/or Substance Abuse Health Conditions Compared with All Others. Albany, NY: New York State Department of Health, Division of Quality and Evaluation, Office of Health Insurance Programs.
11. Holder, H., R. Longabaugh, W.R. Miller & A.V. Rubonis. 1991. The cost-effectiveness of treatment for alcoholism: a first approximation. J. Stud. Alcohol. 52: 517-540.
12. Finney, J.W. & S.C. Monahan. 1996. The cost-effectiveness of treatment for alcoholism: a second approximation. J. Stud. Alcohol. 57: 229-243.
13. McLellan, A.T., D.C. Lewis, C.P. O'Brien & H.D. Kleber. 2000. Drug dependence a chronic medical illness: implications for treatment, insurance and outcomes evaluation. JAMA 284: 1689-1695.
14. Parthasarathy, S., C. Weisner, T.W. Hu & C. Moore. 2001. Association of oupatient alcohol and drug treatment with health care utilization and cost: revisiting the offset hypothesis. J. Stud. Alcohol. 62: 89-97.
15. Weisner, C., J. Mertens, S. Parthasarathy, et al. 2001. Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA 286: 1715-1723.
16. McGlynn, E.A., S.M. Asch, J. Adams, et al. 2003. The quality of health care delivered to adults in the United States. N. Engl. J. Med. 348: 2635-2645.
17. Knudsen, H.K., L.J. Ducharme & P.M. Roman. 2006. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J. Subst. Abuse Treat. 30: 363-373.
18. Ducharme, L.J., H.K. Knudsen & P.M. Roman. 2006. Trends in the adoption of medications for alcohol dependence. J. Clin. Psychopharmacol. 26: S13-S19.
19. Knudsen, H.K., L.J. Ducharme & P.M. Roman. 2009. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. J. Subst. Abuse Treat. 37: 307-312.
20. Center for Substance Abuse Treatment. 2009. Incorporating Alcohol Pharmacotherapies Into Medical Practice. Treatment Improvement Protocol (TIP) Series 49. HHS Publication No. (SMA) 09-4380. Rockville, MD: Substance Abuse and Mental Health Services Administration.
21. National Institute on Drug Abuse. 2009. Principles of Drug Addiction Treatment: a Research-Based Guide. Bethesda, MD: National Institute on Drug Abuse.
22. Knudsen, H.K., A.J. Abraham & P.M. Roman. 2011. Adoption and implementation of medications in addiction treatment programs. J. Addict. Med. 5: 21-27.
23. Knudsen, H.K. & P.M. Roman. 2012. Financial factors and the implementation of medications for treating opioid use disorders. J. Addict. Med. 6: 280-286.
24. Knudsen, H.K., L.J. Ducharme & P.M. Roman. 2007. The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend. 87: 164-174.
25. Knudsen, H.K., A.J. Abraham & C.B. Oser. 2011. Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure. Eval. Program Plann. 34: 375-381.
26. Boswell, K.A., C.L. Cook, S.P. Burch, et al. 2012. Associating medication adherence with improved outcomes: a systematic literature review. AJMC 4: e97-e108.
27. Bailey, J.E., M. Hajjar, B. Shoib, et al. 2012. Risk factors associated with antihypertensive medication on adherence in a statewide Medicaid population. Am. J. Med. Sci. 14: 1-6.
28. Gonzalez, A., J. Barinas & C. O'Cleirigh. 2011. Substance use: impact on adherence and HIV medical treatment. Curr. HIV/AIDS Rep. 8: 223-234.
29. Johnson, K.H., M. Bazargan & E.G. Bing. 2000. Alcohol consumption and compliance among inner-city minority patients with type 2 diabetes mellitus. Arch. Fam. Med. 9: 964-970.
30. Teter, C.J., A.E. Falone, A.M. Bakaian, et al. 2011. Medication adherence and attitudes in patients with bipolar disorder and current versus past substance use disorder. Psychiatry Res. 190: 253-258.
31. Weiss, R.D. 2004. Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction. 99: 1382-1392.
32. Harris, K.M., A. DeVries & K. Dimidjian. 2004. Datapoints: trends in naltrexone use among members of a large private health plan. Psychiatr. Serv. 55: 221.
33. Kranzler, H.R., J.J. Stephenson, L. Montejano, et al. 2008. Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization. Addiction 103: 1801-1808.
34. Bryson, W.C., J. McConnell, T. Krothuis & D. McCarty. 2011. Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization. Am. J. Manag. Care 17: S222-S234.
35. Baser, O., M. Chalk, R. Rawson & D.R. Gastfriend. 2011. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence. Am. J. Manag. Care. 17: S222-S234.
36. Gastfriend, D.R. 2011. Intramuscular extended-release naltrexone: current evidence. Ann. N. Y. Acad. Sci. 1216: 144-166.
37. Zarkin, G.A., J.W. Bray, D. Mitra, et al. 2005. Cost methodology of COMBINE. J. Stud. Alcohol Suppl. 15: 50-55.
38. Wilkerson, J. 2011. PCORI head vows not to do cost-effectiveness studies, but notes gray areas. http://insidehealthpolicy.com/Inside-Health-General/Public-Content/pcori-head-vows-not-to-do-cost-effectiveness-studies-but-notes-gray-areas/menu-id-869.html. Accessed on August 24, 2013
39. Mortimer, D. & L. Segal. 2006. Economic evaluation of interventions for problem drinking and alcohol dependence: do within-family external effects make a difference? Alcohol 41: 92-98.
40. Schwappach, D., S. Popova, S. Mohapatra, et al. 2012. Strategies for evaluating the economic value of drugs in alcohol dependence treatment. Drug Alcohol Depend. 122: 165-173.
41. Reijneveld, S.A. 2000. The cross-cultural validity of self-reported use of health care: a comparison of survey and registration data. J. Clin. Epidemiol. 53: 267-272.
42. Booth, B.M., J.E. Kirchner, S.M. Fortney, et al. 2006. Measuring use of health services for at-risk drinkers: how brief can you get? J. Behav. Health Serv. Res. 33: 254-264.
43. Longo, M.C., S.M. Henry-Edwards, R.E. Humeniuk, et al. 2004. Impact of the heroin 'drought' on patterns of drug use and drug-related harms. Drug Alcohol Rev. 23: 143-150.
44. Ettner, S.L., D. Huang, E. Evans, et al. 2006. Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"? Health Serv. Res. 41: 192-213.
45. Mauskopf, J., S. Sullivan & L. Annemans. 2007. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices-budget impact analysis. Value Health 10: 336-347.
46. UKATT Research Team. 2005. Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ 331: 544.
47. Laine, C., Y.T. Lin, W.W. Hauck & B.J. Turner. 2005. Availability of medical care services in drug treatment clinics associated with lower repeated emergency department use. Med. Care 43: 985-995.
48. Laine, C., W.W. Hauck, M.N. Gourevitch, et al. 2001. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. JAMA 285: 2355-2362.
49. Holder, H.D. 1998. Cost benefits of substance abuse treatment: an overview of results from alcohol and drug abuse. J. Ment. Health Policy Econ. 1: 23-29.
50. Kane, R., M. Wall, S. Potthoff, et al. 2004. The effect of alcoholism treatment on medical care use. Med. Care 42: 395-402.
51. Cartwright, W.S. 2000. Cost-benefit analysis of drug treatment services: review of the literature. J. Ment. Health Policy Econ. 3: 11-26.
52. Harwood, H.J., R.J. Hubbard, J.J. Collins & J.V. Rachal. 1988. The costs of crime and the benefits of drug abuse treatment: a cost-benefit analysis using TOPS data. NIDA Res. Monogr. 86: 209-235.
53. Barnett, P.G. 1999. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction 94: 479-488.
54. Barnett, P.G. 2000. The cost-effectiveness of methadone maintenance. Mt. Sinai J. Med. 67: 365-374.
55. Zaric, G.S., P.G. Barnett & M.L. Brandeau. 2000. HIV transmission and the cost-effectiveness of methadone maintenance. Am. J. Public Health. 90: 1100-1111.
56. Humphreys, K., T.H. Wagner & M. Gage. 2011. If substance use disorder treatment more than offsets its costs, why don't more medical centers want to provide it? A budget impact analysis in the Veterans Health Administration. J. Subst. Abuse Treat. 41: 243-251.
57. Popova, S., S. Mohapatra & J. Patra, et al. 2011. A literature review of cost-benefit analyses for the treatment of alcohol dependence. Int. J. Environ. Res. Public Health. 8: 3351-3364.
58. Zarkin, G.A., J.W. Bray, A. Aldridge, et al. 2008. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients. Arch. Gen. Psychiatry 65: 1214-1221.
59. Dunlap, L.J., G.A. Zarkin, J.W. Bray, et al. 2010. Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients. The patient perspective. Med. Care 48: 306-313.
60. Mark, T.L., L.B. Montejano, H.R. Kranzler, et al. 2010. Comparison of healthcare utilization among patients treated with alcoholism medications. Am. J. Manag. Care 16: 879-888.
61. U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism. 2007. Helping patients who drink too much: a clinician's guide (NIH publication no. 07-3769). http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/guide.pdf. Accessed May 8, 2014.
62. Bryson, W.C., J. McConnell, T. Krothuis & D. McCarty. 2011. Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization. Am. J. Manag. Care 17: S222-S234.
63. Baser, O., M. Chalk, R. Rawson & D.R. Gastfriend. 2011. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence. Am. J. Manag. Care. 17: S222-S234.
64. Kuehn, B.M. 2005. Office-based treatment for opioid addiction achieving goals. JAMA 294: 784-786.
65. Rosenheck, R. & T. Kosten. 2001. Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend. 63: 253-262.
66. Barnett, P.G. 2009. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 104: 982-992.
67. Jones, E.S., B.A. Moore, J.L. Sindelar, et al. 2009. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 99: 132-140.
68. Clark, R.E., M. Samnaliev, J.D. Baxter & G.Y. Leung. 2011. Addiction treatment with buprenorphine: the evidence doesn't justify steps by state medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff. 30: 1425-1433.
69. Baser, O., M. Chalk, D.A. Fiellin & D.R. Gastfriend. 2011. Cost and utilization outcomes of opioid-dependence treatments. Am. J. Manag. Care 17: S235-S246.
70. Minozzi, S., L. Amato, S. Vecchi, et al. 2011. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst. Rev. 2: CD001333.
71. Weiss, R.D., J.S. Potter, D.A. Fiellin, et al. 2011. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch. Gen. Psychiatry 68: 1238-1246.
72. McCarty, D., R. Frank & G. Denmead. 1999. Methadone maintenance and state Medicaid managed care programs. Milbank Q. 77: 341-62.
73. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. 2010. The DAWN Report: Trends in Emergency Department Visits Involving Nonmedical Use of Narcotic Pain Relievers. http://www.samhsa.gov/data/2k10/dawn016/opioided.htm. Accessed May 8, 2014
74. Zarkin, G.A., L.J. Dunlap & G. Homsi. 2004. The substance abuse services cost analysis program (SASCAP): a new method for estimating drug treatment services cost. Eval. Program Plann. 23: 35-43.
75. National Institute on Drug Abuse (NIDA). 2012. Principles of Drug Abuse Treatment for Criminal Justice Populations: a research-based guide (NIH No. 11-5316). Rockville MD: National Institute of Health.
76. Simpson, D.D. 1981. Treatment for drug abuse. Follow-up outcomes and length of time spent. Arch. Gen. Psychiatry. 38: 875-880.
77. Strang, J., T. Babor, J. Caulkins, et al. 2012. Drug policy and the public good: evidence for effective interventions. Lancet 379: 71-83.
78. Schneeweiss, S. & J. Avorn. 2005. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J. Clin. Epidemiol. 58: 323-337.
79. Office of National Drug Control Policy. 2013. National Drug Control Strategy 2013. http://www.whitehouse.gov//sites/default/files/ondcp/policy-and-research/ndcs_2013.pdf. Accessed October 7, 2013.
80. Hartung, D., D. McCarty, R. Fu, et al. 2014. Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies. J. Subst. Abuse Treat. 47: 113-121.
81. Wedam, E.F., G.E. Bigelow, R.E. Johnson, et al. 2007. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch. Intern. Med. 167: 2469-2475.
82. Tkacz, J., J. Severt, J. Cacciola & C. Ruetsch. 2011. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. Am. J. Addict. 21: 55-62.
83. Kaur, A.D., A. McQueen & S. Jan. 2008. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use. J. Manag. Care Pharm. 14: 186-194.
84. Jan, S. & P. Gill. 2011. Utilization patterns of extended-release naltrexone for alcohol dependence. Am. J. Manag. Care 17: S210-S212.
85. American Society of Addiction Medicine. 2013. Public Policy Statement on Pharmacological Therapies for Opioid Use Disorder. http://www.asam.org/docs/default-source/publicy-policy-statements/pharmacological-therapies-for-opioid-use-disorder-2013-04-24.pdf?sfvrsn=4. Accessed on April 7, 2014.
86. Institute of Medicine. 2009. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: National Academies Press.
87. Schwappach, D.L. & T.A. Boluarte. 2007. HEE-GER: a systematic review of German economic evaluations of health care published 1990-2004. BMC Health Serv. Res. 7: 7.
88. McCollister, K.E. & M.T. French. 2003. The relative contribution of outcome domains in the total economic benefit of addiction interventions: a review of first findings. Addiction 98: 1647-1659.
89. Zarkin, G.A., J.W. Bray, A. Aldridge, et al. 2010. The effect of alcohol treatment on social costs of alcohol dependence results from the COMBINE study. Med. Care 48: 396-401.
90. Center for Addiction and Substance Abuse. 2010. Behind Bars II: Substance Abuse and America's Prison Population. New York, NY: CASA.
91. Godfrey, C., D. Stewart & M. Gossop. 2004. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). Addiction 99: 697-707.
92. Cuellar, A.E. & J. Cheema. 2012. As roughly 700, 000 prisoners are released annually, about half will gain health coverage and care under federal laws. Health Aff. (Millwood) 31: 931-938.
93. Mechanic, D. 2012. Seizing opportunities under the Affordable Care Act for transforming the mental and behavioral health system. Health Aff. (Millwood). 31: 376-382.
94. ABC News. June 6, 2013. Poll: Drug Treatment Favored Over Jail. http://abcnews.go.com/Politics/story?id=120958&page=1. Accessed on May 8, 2014.
95. The Economist. August 17, 2013. America's overcrowded prisons-One nation, behind bars: Eric Holder's ideas for locking up fewer Americans are welcome, but do not go far enough. http://www.economist.com/news/leaders/21583680-eric-holders-ideas-locking-up-fewer-americans-are-welcome-do-not-go-far-enough-one. Accessed on May 8, 2014.